The study aimed to investigate how TBI affects the risk of secondary malignancies in long-term AML survivors post-allo-HSCT. Researchers found an inverse relationship between TBI doses and secondary malignancies, but age and competing risks complicate the results. Total body irradiation (TBI)-based allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for certain […]
Consolidation Durvalumab Enhances Survival in LS-SCLC vs Placebo
The study aimed to analyze the impact of consolidation Durvalumab on outcomes on subgroups based on cCRT and PCI. The primary endpoint was OS and PFS. Consolidation Durvalumab improved survival compared to placebo, supporting it as the new standard for LS-SCLC. In the ADRIATIC trial, consolidation treatment with Durvalumab vs placebo significantly boosted […]
Periop Chemo Alone vs Preop CRT in Resectable Gastric Cancer
The TOPGEAR phase II & III trial aimed to assess if adding preop CRT to periop CT improves outcomes in resectable gastric cancer. The primary endpoint was to determine OS. The preop CRT improves pathological outcomes but does not enhance OS compared to periop CT alone. In Western countries, resectable gastric cancer is […]
Efficacy of Ramucirumab Plus TAS102 in Heavily Treated mCRC
The study aimed to investigate the impact of adding ramucirumab to trifluridin/tipiracil in heavily pretreated mCRC. The primary endpoint was to determine OS and the secondary endpoints were DCR, PFS and safety. Researchers noted that ramucirumab improved survival in select heavily pretreated patients with mCRC, indicating the need for personalized treatment. Patients with […]
Prospective Evidence of Adjuvant Aspirin in PIK3CA Colon Cancer
The SAKK 41/13 phase III trial verified the benefits of adjuvant aspirin for patients with PIK3CA-mutant colon cancer. The primary endpoint was to determine DFS and the secondary endpoints were OS & AEs. Aspirin showed a 43% DFS improvement in PIK3CA-mutant colon cancer. Several retrospective studies suggest a potential protective effect of aspirin […]
Impact of Metformin on OS in mHSPC: STAMPEDE
The study aimed to assess the effect of metformin on OS and metabolic outcomes in mHSPC with ADT. Metformin did not improve survival in all metastatic patients but enhanced outcomes and metabolic parameters in high-volume cases. Metformin is a commonly used and well-tolerated anti-diabetic medication. Previous research indicates that metformin may possess anti-cancer […]
MOST RECENT
Survival Impact of R2 Resection vs. No Surgery in EOC
The study aimed to compare survival outcomes between patients with advanced EOC having R2 resection and those with no surgery. The primary endpoints were to determine PFS and OS. Researchers noticed that despite the uniformly unfavorable prognosis, R2 resection may still offer a survival advantage over no surgery. Cytoreductive surgery is essential for […]
Adipocyte Exosomes Enhance Invasion and Paclitaxel in EOC
The study aimed to investigate the role of omental adipocyte-derived exosomes in promoting EOC invasion and resistance to paclitaxel chemotherapy. Researchers noticed that omental adipocytes foster a tumor-friendly and chemoresistant environment in OC. Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer, with high mortality rates often attributed to chemotherapy resistance. EOC […]
Evaluating SeDAR E-Health Video for CC Screening Uptake
The study aimed to investigate the effectiveness of the e-health video in enhancing motivation and uptake of CC screening among young women. Researchers noticed that the SeDAR® e-health video significantly improved motivation and uptake of CC screening. The incidence of cervical cancer (CC) is rising among women under 50, even though early screening […]
Impact of ctDNA Clearance With D+T+EV in MIBC: VOLGA SRI
The VOLGA phase 3 trial aimed to investigate the link between plasma ctDNA clearance and clinical outcomes in patients with MIBC receiving neoadjuvant D+T+EV. The primary endpoints were to determine Pathologic Response & EFS. Researchers observed that plasma ctDNA clearance may predict better outcomes with neoadjuvant D+T+EV in MIBC; further investigation is ongoing. […]
Advertisement
MOST RECENT
Popular With Peers
SKB264 + KL-A167 Shows Promise in NSCLC: OptiTROP-Lung01
The study aimed to assess the efficacy and safety of combining SKB264 with KL-A167 in patients with advanced NSCLC. Researchers observed that SKB264 + KL-A167 demonstrated promising efficacy and safety; further investigation is ongoing. Sacituzumab Tirumotecan (SKB264/MK-2870) is a TROP2 ADC developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase […]
Efficacy of Fulzerasib/Cetuximab in KRAS G12C NSCLC
The phase 1 & 2 trial aimed to investigate the efficacy and safety of combining fulzerasib, with cetuximab as front-line treatment for patients with NSCLC. The primary objective was to evaluate fulzerasib with cetuximab in untreated advanced NSCLC with KRAS G12C mutation. Researchers noticed promising efficacy and safety of fulzerasib + cetuximab; further […]
TN+ SPA or RIB Therapies: Safe & Tolerated
The phase I trial aimed to assess TN’s safety and efficacy combined with SPA or RIB in advanced solid tumor patients. The results demonstrated that TN combined with SPA or RIB was well-tolerated at recommended doses, with safety profiles consistent with individual agents. Omar Saavedra Santa Gadea and the team spearheaded the study […]
VenDd Elicits Durable MRD Negativity in Myeloma
The interventional phase 2 trial aimed to compare MRD in VenDd vs. DVd RRMM. The results demonstrated that VenDd was superior MRD clearance and extended PFS in t(11;14)-positive RRMM compared to DVd. Multiple myeloma shows hematologic malignancies that involve abnormal cell proliferation in the bone marrow—the combination of venetoclax (Ven), a potent BCL-2 […]
Combined Efficacy of Tucatinib and Trastuzumab for HER2-Positive MBTC
The phase II trial aimed to evaluate the combined efficacy and safety of TUC and Tras in HER2-altered solid tumor pts. The primary endpoint was cORR. Secondary endpoints include OS, DCR, DOR, PFS, and safety. The study found that combined therapy was well-tolerated and showed promising antitumor activity in pts. Biliary tract cancer […]
Amivantamab Shows Efficacy In Pts With Advanced NSCLC
The phase 1 CHRYSALIS study evaluated amivantamab (ami) for treating advanced non-small cell lung cancer with EGFR Ex20ins mutations. Patients who had experienced disease progression on platinum-based chemotherapy were enrolled in the study. The study demonstrated the effectiveness of amivantamab in treating advanced NSCLC with EGFR Ex20ins mutations across diverse patient groups and […]
PSCA-Targeted CAR T Cells Show Promise in mCRPC Patients
The phase I trial aimed to evaluate the safety and efficacy of PSCA-targeted 4-1BB-co-stimulated CAR T cell therapy in patients with mCRPC. CAR T cells were manufactured and infused into patients with disease progression after at least 1 androgen receptor-targeted therapy. The study found that PSCA-CAR T cells can potentially treat mCRPC, but […]
CheckMate 214 Study: Clinical Efficacy of NIVO+IPI in sRCC Patients
Phase 3 of CheckMate 214 trial was conducted to study the long-term efficacy and suitability of NIVO+IPI as a 1L treatment for patients with Untreated Advanced or Metastatic Renal Cell Carcinoma with Sarcomatoid features. 139 patients were randomized in an open-label trial to compare the NIVO+IPI combination with SUN monotherapy, where NIVO+IPI proved […]
ctDNA Testing in mCRPC Patients with HRR Gene Alterations
The phase 3 PROfound study included patients with mCRPC whose plasma samples were retrospectively sequenced using circulating tumor DNA (ctDNA) Next-Generation Sequencing (NGS) to test for BRCA/ATM alterations. The efficacy of Olaparib was consistent, irrespective of the method used to identify the BRCA/ATM alterations. The study demonstrated that ctDNA NGS might be used […]
Enrolling Trials
Sign up for our emails
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Newsletter
Privacy Policy
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
SELECT ONCOLOGY JOURNAL ARTICLES
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …
1222 Antigen-specific delivery of TCR and costimulatory signals by a protein scaffold selectively activates and markedly expands naïve MART-1-specific CD8+ T cells
1222 Antigen-specific delivery of TCR and costimulatory signals by a protein scaffold selectively activates and markedly expands naïve MART-1-specific CD8+ T cells
Background Adoptive cell transfer (ACT) shows promise as an immunotherapy for melanoma and other cancers. However, there are several challenges associated with ACT such as the logistical complexity and inconsistency when using patient-derived antigen-presenting cells for …
890 Nivolumab plus ipilimumab in anti-PD(L)-1 naïve and experienced HCC patients -- single institute experience in Taiwan
890 Nivolumab plus ipilimumab in anti-PD(L)-1 naïve and experienced HCC patients -- single institute experience in Taiwan
Background Immune checkpoint inhibitors (ICIs) are standard therapy for advanced hepatocellular carcinoma (HCC). However, the efficacy of combining nivolumab and ipilimumab in Anti-PD(L)-1 Naïve and Experienced HCC patients remains unclear. Methods We retrospectively reviewed 23 patients with advanced …
778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma
778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma
Background Novel early-line therapies for advanced (unresectable or metastatic) melanoma are needed to improve the rate of deep and durable responses and increase the proportion of patients with long-term benefit. TILVANCE-301 will evaluate the efficacy and …